Add to My Stocks
$3.3 $0 (0%) PCSA stock closing price Sep 18, 2018 (Closing)

The financial analysis of PCSA requires an investor to check the cash flows for PROCESSA PHARMA. While its important to look at the PROCESSA PHARMA debt position, the cash flow statement becomes equally important because public companies use accrual accounting. For example, if a company sells a product which gets counted as PROCESSA PHARMA revenue but does not convert to cash because it does not receive payment in the same quarter, it affects the cash position for that period. PROCESSA PHARMA cash flow analysis is possible because this statement breaks down how balance sheet accounts and income statement items affect cash and cash equivalents. PROCESSA PHARMA had cash and cash equivalents of $1.07M at the beginning of the year and $2.84M at year end for 2017. PROCESSA PHARMA has a positive cash and cash equivalents change of $1.77M.

View details of PROCESSA PHARMA cash flows for latest & last 10 financial years
show more
Fiscal year is Jan - Dec2017201620152014
Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow----
Net Increase (Decrease) in Assets Liabilities----0.25M
Cash From (used in) Discontinued Operations--0.01M--
Other Adjustments Net--1.95M1.59M
Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment-0.02M---0.01M
Acquisition Disposition of Subsidiaires----
Increase (Decrease) in Investments1.01M---
Other Cash Inflow (Outflow) from Investment Activities----0.03M
Net Cash from (used by) Investment Activities
Issuance (Purchase) of Equity Shares----
Issuance (Repayment) of Debt Securities2.58M---0.04M
Increase (Decrease) in Bank & Other Borrowings---1.74M
Payment of Dividends & Other Cash Distributions----
Other Cash from (used by) Financing Activities-0.15M---
Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash----
Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year1.07M---
Cash & Equivalents at Year End2.84M---
All figures in USD. M: Millions of USD, B: Billions of USD.

The statement of cash flows comprises of cash flow from financing, cash flow from operations and cash flow from investing activities. All the three can have an impact on the stock price. The PROCESSA PHARMA stock price history and PROCESSA PHARMA stock comparison chart inevitably reflect its cash flow situation.

  • Net Change in Cash and Cash Equivalents: A positive net change in cash and cash equivalents shows that PROCESSA PHARMA is able to meet its expenditure and grow cash at hand which demonstrates the financial strength of the company's balance sheet. Also see - PROCESSA PHARMA stock price movement.
  • The cash generated from the core business or operations was a negative at $-1.65M for PROCESSA PHARMA in the latest 2017. For an internet company, this would include all those activities which are involved in eventually selling advertisement space on its website or any online service.
  • Growth companies, typically most tech companies; spend heavily on investing activities and this figure stood at $1M for PCSA stock. Sometimes a company might have a negative overall cash flow which may not be really bad if it is due to investment expenses. Hence it is important to check the cash flow from investment activities.
  • Inflow of cash in the form of bank loans and shareholders equity, and outflow of cash because of dividend payments, share repurchase payments etc. come under financing activities. The cash generated from these activities was $2.42M for PROCESSA PHARMA.

Key Financial Ratios For PROCESSA PHARMA Cash Flow

FCF margin